SCHEMBL7075686

SCHEMBL7075686

CN(C)C(=O)Oc1ccccc1-c1cc(=O)c2ccccc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.56
CYP3A4 P08684 7/20 0.56
CYP2C19 P33261 5/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
ALDH1A1 P00352 5/20 0.56
MAPT P10636 5/20 0.56
CYP2C9 P11712 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
RAB9A P51151 3/20 0.56
CYP2D6 P10635 3/20 0.56
MAPK1 P28482 3/20 0.56
TSHR P16473 2/20 0.56
NPC1 O15118 2/20 0.56
TP53 P04637 2/20 0.56
ALOX15 P16050 2/20 0.56
GMNN O75496 1/20 0.56
RAF1 P04049 1/20 0.56
CYP1A2 P05177 1/20 0.56
PKM P14618 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081024 0.88 BCHE (0.58) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL7207949 0.88 MEN1 (0.53) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL7075370 0.84 KDM4E (0.53) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL7081030 0.82 AR (0.60) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL253522 0.80 HPGD (0.78) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL7134490 0.78 TNKS (0.57) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL21633838 0.77 HPGD (0.66) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL23581452 0.76 AKR1C3 (0.61) HPGDCYP3A4CYP2C19MEN1KMT2A
SCHEMBL29080547 0.76 HPGD (0.61) HPGDCYP3A4CYP2C19MEN1KMT2A
Hydrochloric Acid SCHEMBL7376415 0.76 SIGMAR1 (0.57) HPGDCYP3A4CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US claimed
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US disclosed
EP-1322632-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES Biogal Pharmaceutical Co., Ltd (HU) 2003-07-02 EP disclosed
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-09-12 US disclosed
WO-2002024677-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-03-28 WO disclosed
WO-2002024676-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones CBR3, FOS, CBR1 HPGD 2446/4885CYP3A4 1040/4885CYP2C19 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.